{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:14:06Z","timestamp":1780445646499,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Patients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the management of sepsis in Chinese patients with hematological diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was conducted on hematological diseases patients diagnosed as sepsis and treated with CMS at the First Affiliated Hospital of Soochow University between November 2021 and July 2023. Demographics, clinical presentation, causative organisms, clinical outcomes and adverse events (AEs) were recorded. The univariate and multivariate analysis was conducted to identify predictive factors for clinical effectiveness and renal insufficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 81 hematological patients diagnosed with sepsis were included, the mean (change in sequential organ failure assessment [SOFA] score) \u0394SOFA when utilizing CMS was 3.90 \u00b1 2.10. Following CMS treatment, a clinical effectiveness rate was observed in 62.96% of patients, while the bacteriological eradication rate was 60.23%. Additionally, the 28-day all-cause mortality rate was 29.63%. The median length of stay in the ICU and total in-hospital stay was 13.5 and 33 days, respectively. AEs were reported in 16 patients (19.75%), including 15 (18.52%) renal insufficiency, 1 (1.23%) hepatic insufficiency, and 1 (1.23%) rash. The multivariate analysis of clinical effectiveness indicated that a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score, a higher Charlson comorbidity index, the relapse or refractory of hematological diseases, septic shock, and the use of mechanical ventilation was independently associated with a poor clinical effectiveness. The univariate analysis of renal insufficiency demonstrated that allogeneic hematopoietic stem cell transplantation, aplastic anemia, and gastrointestinal infection had a statistically significant impact on renal function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The findings of our study demonstrated that CMS was an efficacious treatment for sepsis in Chinese patients with hematological diseases, while concurrently exhibiting an acceptable toxicity profile.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1613414","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:32:50Z","timestamp":1755063170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s15010-013-0471-6","article-title":"Colistin is relatively safe in hematological Malignancies and hematopoietic stem cell transplantation patients","volume":"41","author":"Averbuch","year":"2013","journal-title":"Infection"},{"key":"B2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s12885-021-08452-w","article-title":"A 12-year study evaluating the outcomes and predictors of mortality in critically ill cancer patients admitted with septic shock","volume":"21","author":"Awad","year":"2021","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1200\/jco.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic Malignancies: prospective multicenter data from France and Belgium\u2013a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study","volume":"31","author":"Azoulay","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijantimicag.2009.11.016","article-title":"Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections","volume":"35","author":"Cheng","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/cid\/cis286","article-title":"High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study","volume":"54","author":"Dalfino","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2169\/internalmedicine.50.4270","article-title":"Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic Malignancy: a matched pair analysis","volume":"50","author":"Durakovic","year":"2011","journal-title":"Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/0885066616646551","article-title":"Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multidrug-resistant gram-negative pneumonia","volume":"32","author":"Elefritz","year":"2017","journal-title":"J. Intensive Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.mcna.2020.02.011","article-title":"Sepsis and Septic Shock - Basics of diagnosis, pathophysiology and clinical decision making","volume":"104","author":"Font","year":"2020","journal-title":"Med. Clin. North Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s15010-017-1010-7","article-title":"Good tolerability of high dose colistin-based therapy in patients with haematological Malignancies","volume":"45","author":"Grignolo","year":"2017","journal-title":"Infection"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2020009","DOI":"10.4084\/mjhid.2020.009","article-title":"Febrile neutropenia in acute leukemia. Epidemiology, etiology, pathophysiology and treatment","volume":"12","author":"Hansen","year":"2020","journal-title":"Mediterr J. Hematol. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jiac.2020.10.024","article-title":"Efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant gram-negative bacilli","volume":"27","author":"Kagami","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiph.2023.05.024","article-title":"Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study","volume":"16","author":"Katip","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050484","article-title":"Short-course versus long-course colistin for treatment of carbapenem-resistant A.baumannii in cancer patient","volume":"10","author":"Katip","year":"2021","journal-title":"Antibiot. (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010031","article-title":"Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients","volume":"14","author":"Katip","year":"2021","journal-title":"Pharmaceutics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00277-019-03622-0","article-title":"Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"98","author":"Kochanek","year":"2019","journal-title":"Ann. Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3760\/cma.j.issn.0253-2727.2022.12.011","article-title":"Treatment of infection by Ceftazidime Avibactam in hematopathy patients due to neutropenia","volume":"43","author":"Kong","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijid.2020.01.022","article-title":"The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital","volume":"93","author":"Li","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13054-024-04932-0","article-title":"Sepsis mortality among patients with haematological Malignancy admitted to intensive care 2000-2022: a binational cohort study","volume":"28","author":"MacPhail","year":"2024","journal-title":"Crit. Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.6004\/jnccn.2021.7046","article-title":"Outcomes and predictors of 28-day mortality in patients with hematologic Malignancies and septic shock defined by sepsis-3 criteria","volume":"20","author":"Manjappachar","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cpt.582","article-title":"Colistin reduces LPS-triggered inflammation in a human sepsis model in vivo: A randomized controlled trial","volume":"101","author":"Matzneller","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1282464","article-title":"Utilizing liposomal encapsulation approach to address nephrotoxic challenges of colistimethate sodium through a preclinical study","volume":"14","author":"Mektrirat","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ijid.2020.08.010","article-title":"Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study","volume":"100","author":"Moni","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s11912-022-01226-y","article-title":"Antibiotic management of patients with hematologic Malignancies: from prophylaxis to unusual infections","volume":"24","author":"Moreno-Sanchez","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the last-line polymyxins: achievements and challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.ackd.2019.08.005","article-title":"Nephrotoxic chemotherapy agents: old and new","volume":"27","author":"Nicolaysen","year":"2020","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/cmr.00064-16","article-title":"Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes","volume":"30","author":"Poirel","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"15261","DOI":"10.1038\/s41598-022-19626-2","article-title":"Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections","volume":"12","author":"Sadyrbaeva-Dolgova","year":"2022","journal-title":"Sci. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the american college of clinical pharmacy (ACCP), european society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of america (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1378\/chest.13-1018","article-title":"Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria","volume":"144","author":"Tumbarello","year":"2013","journal-title":"Chest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"18348","DOI":"10.1038\/s41598-023-45256-3","article-title":"A quantitative method for determination of colistin E2 methanesulphonate in human plasma by (15)N-labeled colistin E2","volume":"13","author":"Xu","year":"2023","journal-title":"Sci. Rep."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1156651","article-title":"Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases","volume":"13","author":"Zhen","year":"2023","journal-title":"Front. Cell Infect. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1613414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:32:51Z","timestamp":1755063171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1613414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":31,"alternative-id":["10.3389\/fcimb.2025.1613414"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1613414","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1613414"}}